Call Number (LC) Title Results
RA401.A1 P69 2006eb The power of pills : social, ethical, and legal issues in drug development, marketing, and pricing / 1
RA401.A1 R38 2002 Effective drug regulation : a multicountry study / 1
RA401.A1 -- R38 2002eb Effective Drug Regulation : a Multicountry Study. 1
RA401.A1 .R384 2012 Recent Trends on QSAR in the Pharmaceutical Perceptions. 1
RA401.A1 R63 2011  
RA401.A1 R63 2011eb Pharmaceutical reform : a guide to improving performance and equity / 1
RA401.A1 S45 2010 A practical approach to pharmaceutical policy / 1
RA401.A1 S94 National authorities empowered to issue certificates and authorizations for the import and export of narcotic drugs / 1
RA401.A1 T73 2021eb Transparency, power, and influence in the pharmaceutical industry : policy gain or confidence game? / 1
RA401.A1 W36 2009 Global health partnerships : the pharmaceutical industry and BRICA / 1
RA401.A1 W36 2009eb Global health partnerships the pharmaceutical industry and BRICA /
Global health partnerships : the pharmaceutical industry and BRICA / 		2
RA401.A1 W672 2007 WHO Expert Committee on Biological Standardization. 1
RA401.A3 Pharmaceutical public policy
Public Health, Personal Health and Pills : Drug Entanglements and Pharmaceuticalised Governance.
The FDA for doctors /
Pharmaceutical public policy /
Drug wars : how big pharma raises prices and keeps generics off the market / 		5
RA401.A3 \ Defining Drugs : How Government Became the Arbiter of Pharmaceutical Fact / 1
RA401.A3 A83 1985 Orphan drugs : medical versus market value / 1
RA401.A3 B47 1994 Uniform pharmaceutical pricing : an economic analysis / 1
RA401.A3 B74 2009 Breakthrough business models : drug development for rare and neglected diseases and individualized therapies : workshop summary / 1
RA401.A3 B74 2009eb Breakthrough business models : drug development for rare and neglected diseases and individualized therapies: workshop summary / 1
RA401.A3 C37 2010 Reputation and power : organizational image and pharmaceutical regulation at the FDA / 1
RA401.A3 C37 2010eb Reputation and power organizational image and pharmaceutical regulation at the FDA /
Reputation and power : organizational image and pharmaceutical regulation at the FDA / 		2